Cite

    C. Schmid et al.. “Immune modulation of AML-blasts in therapy-refractory AML-patient in vivo with clinically approved response modifiers improves clinical status, blood cell regeneration and gives rise to leukemia specific adaptive and innate immune reactive cells.” European journal of cancer, vol. 92, n.d., pp. S15–. http://access.bl.uk/ark:/81055/vdc_100058290613.0x00001b